



PEOPLE

William A. Albright, Jr. has been promoted to CEO of Nexell Therapeutics (Irvine, CA) and will assume a seat on the company's board of directors. **Richard L. Dunning**, who had served as CEO since 1996, will remain chairman of the board. Mr. Albright will also retain the title of president but the position of chief operating officer, which he held since July 2000, will be eliminated.

Frank Baldino, chairman, CEO, and founder of Cephalon, has joined the board of directors of NicOx (Sophia-Antipolis, France). He replaces **Denis Lucquin** of Sofinnova Partners.

Gregg D. Beloff has been appointed vice president and chief financial officer of ImmunoGen (Cambridge, MA). Mr. Beloff was most recently a vice president in the healthcare investment banking group of Adams, Harkness & Hill.

EPIX Medical (Cambridge, MA) has announced the appointment of **Alan Carpenter** as executive vice president of R&D. Dr. Carpenter was most recently vice president of medical imaging R&D at DuPont Pharmaceuticals.

Robert A. Essner has been elected as the next CEO of American Home Products (Madison, NJ), succeeding **John Stafford**. Mr. Essner will continue as president and as a member of the company's board of directors. He is currently president and COO. Mr. Stafford will remain as chairman of the AHP board.

Gillian Francis has resigned her position as managing director of PolyMASC Pharmaceuticals, a wholly owned subsidiary of Valentis (Burlingame, CA), and as a member of the Valentis board of directors, to pursue other interests. Dr. Francis will continue to serve as a consultant to the company.

Larry Greller has been appointed director of mathematical biology and systems modeling at Molecular Mining Corp. (Kingston, Ontario, Canada). He was formerly assistant director of bioinformatics mathematical biology at SmithKline Beecham Pharmaceuticals R&D.

Corvas International (San Diego, CA) has named **Stephen F. Keane** vice president, corporate development, a newly created position. Mr. Keane has held senior corporate development positions with Epimmune, SIBIA Neurosciences, and Molecular Biosystems.

ConjuChem (Montreal, Quebec, Canada) has announced the appointment of **Jacques**

Lapointe to its board of directors. Mr. Lapointe is president, COO, and a board member of BioChem Pharma, and was previously president and CEO of Glaxo Wellcome Canada and Glaxo Wellcome UK.

Nathan P. Letts has been named director, intellectual property of diaDexus (Santa Clara, CA). Dr. Letts was most recently a patent attorney at Pennie & Edmonds. The company also named **Maureen Wang**, former director of recombinant DNA technology at Hyseq, as director, molecular biology.

Antigenics (New York) has elected **Sanford M. Litvack**, most recently vice chairman of the board of The Walt Disney Company, to its board of directors. Mr. Litvack served as Disney's senior vice president and COO from 1994 to 1999 and was a member of its board of directors since April 1995.



Transkaryotic Therapies (Cambridge, MA) has announced that **Anthony S. Murabito** has joined the company as vice president, management information systems. Previously, Mr. Murabito directed the global

information management department at SmithKline Beecham. In addition, **Daniel E. Geffken** has been promoted to the position of senior vice president, finance and CFO. Mr. Geffken joined TKT in 1997.



Astex Technology (Cambridge, UK) has announced the appointment of **Chris Murray** as head of computational chemistry and **Jeff Yon** as head of protein technology. Dr. Murray previously held the same position at Protherics. Dr. Yon joins Astex from Janssen Research Foundation, where he was a group leader and in charge of protein production.

ImaRx Therapeutics (Tucson, AZ) has announced that **Nina Ossanna** is joining the company as senior director of business development. Dr. Ossanna comes to ImaRx from The Johns Hopkins University School of Medicine, where she was most recently director of the office of technology licensing.

Cytoclonal Pharmaceuticals (Dallas, TX) has named **Robert J. Rousseau** vice president of business development and licensing. Dr. Rousseau previously served as director of new technologies licensing at Hoechst Marion Roussel.